

Feb. 19, 2026  
 Listing Department  
 Tokyo Stock Exchange, Inc.

### Outline of Initial Listing Issue

Company Name	J-Pharma Co.,Ltd.
Scheduled Listing Date	Mar. 25, 2026
Market Section	Growth Market
Current Listed Market	N/A
Name and Title of Representative	YOSHITAKE Masuhiro, President & CEO
Address of Main Office	1-10-11, HamamatsuCho, Minato-Ku Tokyo, 105-0013 Tel. +81-3-6432-4270
(Closest Point of Contact)	(Same as above)
Home Page	<a href="https://www.j-pharma.com/en/">https://www.j-pharma.com/en/</a>
Date of Incorporation	Dec. 26, 2005
Description of Business	Drug discovery and development targeting SLC transporters
Category of Industry / Code	Pharmaceutical / 520A (ISIN JP3387030004)
Authorized Total No. of Shares to be Issued	58,358,000 shares
No. of Issued Shares	14,589,610 shares (As of Feb. 19, 2026)
No. of Issued Shares (incl. treasury shares) at the Time of Listing	17,829,610 shares
Capital	(Note 1) The number includes newly issued shares issued through the public offering.
No. of Shares per Share Unit	(Note 2) The number could increase as a result of the exercise of share options, etc.
Business Year	JPY 682,700 thousand (As of Feb. 19, 2026)
General Shareholders Meeting Record Date	100 shares
Record Date of Surplus Dividend Transfer Agent	From Apr. 1 to Mar. 31 of the following year
Auditor	Within 3 months after the end of the business year
Managing Trading Participant	Mar. 31
	Sep. 30 and Mar. 31
	Sumitomo Mitsui Trust Bank, Limited
	GINGA AUDIT CORPORATION
	SBI SECURITIES Co.,Ltd.

## &lt;Overview of Public Offering and Secondary Distribution &gt;

Public Offering / Secondary Distribution	Public Offering (Newly Issued Shares) Secondary Distribution (Placement Underwritten and Purchased by Principal Underwriting Participants) Secondary Distribution (Placement by over-allotment scheme)	3,240,000 shares 200 shares 486,000 shares
Original Share Offerors	Eight Roads Ventures Japan II L.P F-Prime Capital Partners Life Sciences Fund VI LP	100 shares 100 shares
Offering Price	Book-building method	
Determination Method	Mar. 5, 2026	
Provisional Conditions		
Determination Date	Mar. 6, 2026 to Mar. 12, 2026	
Book-building Period	Mar. 13, 2026	
Offering Price		
Determination Date	Mar. 16, 2026 to Mar. 19, 2026	
Subscription Period	Mar. 24, 2026	
Payment Date	Mar. 25, 2026	
Settlement Date		
Principal Underwriting Participants	SBI SECURITIES Co.,Ltd. Daiwa Securities Co. Ltd. Tokai Tokyo Securities Co., Ltd. TOYO SECURITIES CO.,LTD. MATSUI SECURITIES CO.,LTD. Monex, Inc. Rakuten Securities, Inc.	

(Note 1) Tokyo Stock Exchange, Inc. approves new listings based on the results of the examination by Japan Exchange Regulation.

(Note 2) The “Initial Listing Application Securities Report (Part I)” (only in Japanese) of the company is available on the JPX official website. Please refer to such release for details.

(Note 3) Buy and sell market orders for this issue are prohibited in transactions carried out up to and including the initial price determination date.